Bleomycin (hydrochloride)

Bleomycin (hydrochloride)

• CAS Number: 67763-87-5
• UNSPSC Description: Bleomycin hydrochloride is a DNA synthesis inhibitor. Bleomycin hydrochloride is a DNA damaging agent. Bleomycin hydrochloride is an antitumor antibiotic[1].
• Target Antigen: Antibiotic; DNA/RNA Synthesis
• Type: Reference compound
• Related Pathways: Anti-infection;Cell Cycle/DNA Damage
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/bleomycin-hydrochloride.html
• Solubility: DMSO : 50 mg/mL (ultrasonic;warming;heat to 60°C)|H2O : 100 mg/mL (ultrasonic)
• Smiles: O=C(C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C)N[C@H](C(N[C@H](C)[C@@H](O)[C@H](C)C(N[C@]([C@H](O)C)([H])C(NCCC2=NC(C3=NC(C(N[R])=O)=CS3)=CS2)=O)=O)=O)[C@H](C4=CN=CN4)O[C@H]5[C@H]([C@H]([C@@H]([C@@H](O5)CO)O)O)O[C@]6([H])[C@H]([C@H]([C@@H]([C@H](O6)CO)O)OC(N)=O)O.NC(NCCCC[R])=N.[R]CCC[S+](C)C.[H]Cl.[R=].[Bleomycin A2].[R=].[Bleomycin B2]
• References & Citations: [1]Hovhannisyan G, et al. Comparative analysis of individual chromosome involvement in micronuclei induced by bleomycin in human leukocytes. Mol Cytogenet. 2016 Jun 21;9:49.|[2]Jaaskela-Saari HA, et al. Squamous cell cancer cell lines: sensitivity to bleomycin and suitability for animal xenograft studies. Acta Otolaryngol Suppl. 1997;529:241-4.|[3]Corboz MR, et al. Therapeutic administration of inhaled INS1009, a LRX-15 prodrug formulation, inhibits bleomycin-induced pulmonary fibrosis in rats. Pulm Pharmacol Ther. 2018 Apr;49:95-103.|[4]Kang Miao, et al. Scutellarein inhibits BLM-mediated pulmonary fibrosis by affecting fibroblast differentiation, proliferation, and apoptosis. Ther Adv Chronic Dis. 2020 Jul 30;11:2040622320940185.|[5]Ling Peng, et al. Scutellarin ameliorates pulmonary fibrosis through inhibiting NF-κB/NLRP3-mediated epithelial-mesenchymal transition and inflammation. Cell Death Dis. 2020 Nov 13;11(11):978.Am J Respir Cell Mol Biol. 2021 Apr 16.|Am J Respir Cell Mol Biol. 2021 Mar 24.|Am J Respir Cell Mol Biol. 2021 Oct 28.|Biomed Pharmacother. 2021, 111500.|Biomed Res Int. 2022 Feb 7;2022:8752325.|Bioorg Med Chem. 2024 Sep 12.|Cancer Lett. 2022 Feb 9;532:215588.|Cancers (Basel). 2024 Aug 21;16(16):2902.|Cell Death Dis. 2020 Nov 13;11(11):978.|Cell Signal. 2021 Aug 4;110106.|Chin Med. 2023 May 24;18(1):60.|Clin Epigenetics. 2023 Nov 11;15(1):182.|Heliyon. 2023 Nov 13.|Heliyon. 2024 Sep 20;10(19):e38122.|Immunopharmacol Immunotoxicol. 2020 Oct;42(5):436-444.|J Cell Biol. 2021 Feb 1;220(2):e201911025.|J Control Release. 2023 Aug;360:365-375.|J Inflamm Res. 2024 Jun 19:17:3983-3999.|J Transl Med. 2024 Apr 1;22(1):323.|Life Sci. 2021 Jan 1;264:118664.|MedComm Futur Med. 2024 Jul 19.|Mediat Inflamm. 03 Mar 2022.|Mol Metab. 2022 Jun 2;101524.|Nat Cell Biol. 2024 Jul 12.|Nat Metab. 2021 Dec 6.|Nat Prod Commun. 2024 Mar 29.|Oxid Med Cell Longev. 01 Nov 2021.|Oxid Med Cell Longev. 30 Jun 2021.|Pharmaceuticals (Basel). 2024 Oct 11;17(10):1360.|Phytomedicine. 2024 Jul 27:133:155882.|Phytother Res. 2022 Jul 6.|Redox Biol. 2021 Jul 26;46:102082.|Res Sq. 2024 Oct 31.|Research Square Preprint. 2023 Aug 4.|Respir Res. 2024 Oct 19;25(1):382.|Rheumatol Autoimmun. 2024 Jun 28.|Sci China Life Sci. 2023 Jun 16.|Sci Rep. 2023 Jun 28;13(1):10485.|Small. 2021 Oct 8;e2103919.|Ther Adv Chronic Dis. 2020 Jul 30;11:2040622320940185.|ACS Appl Mater Interfaces. 2019 Jan 16;11(2):1942-1950. |Am J Physiol Endocrinol Metab. 2024 Aug 28.|Antioxidants (Basel). 2024 May 29;13(6):667.|Biochem Biophys Res Commun. 2020 Jun 30;527(3):662-667.|Biochem Pharmacol. 2020 Apr;174:113846.|Biochem Pharmacol. 2024 Aug 17:116496.|Biomed Pharmacother. September 2022, 113460.|bioRxiv. 2024 July 27.|bioRxiv. 2024 Nov 06.|Cell Death Dis. 2020 Jun 15;11(6):464.|Cell Death Dis. 2020 Nov 12;11(11):976.|Cell Mol Biol Lett. 2024 Aug 30;29(1):115.|Cell Mol Life Sci. 2024 Apr 18;81(1):187.|Cell Rep. 2024 Sep 28;43(10):114794.|Cells. 2021, 10(2), 202.|Cells. 2022 Dec 29;12(1):145.|Cells. 2023, 12(1), 145.|Chinese Journal of Plastic and Reconstructive Surgery. 23 December 2021.|Eur J Pharmacol. 2024 Jul 26:176843.|FEBS J. 2024 Aug 26.|Front Pharmacol. 2022 May 20;13:911945.|Fundamental Research. 23 December 2021.|Gene Rep. 2023 Jul 22, 101823.|Heliyon. 2024 June 23.|Int Immunopharmacol. 2023 Jan 23;116:109723.|Int Immunopharmacol. 2023 Sep 15;124(Pt A):110905.|Int Immunopharmacol. 2024 Jul 6:138:112645.|J Adv Res. 2024 Jun 19:S2090-1232(24)00254-6.|J Ethnopharmacol. 2024 Apr 25:330:118226.|Mech Ageing Dev. 2024 Jan 11:111902.|Mutat Res Genet Toxicol Environ Mutagen. 2016 Sep 15;808:27-37. |Naunyn Schmiedebergs Arch Pharmacol. 2024 Jun 14.|OncoImmunology. 2020 Sep 22;9(1):1824631.|Patent. US20190255042A1.|Patent. US20190282565A1.|Phytomedicine. 2023 Feb 11.|Phytomedicine. 2024 Jun 3:131:155797.|Research Square Preprint. 2023 Aug 30.|Research Square Preprint. 2023 Nov 23.|Research Square Print. November 28th, 2022.|Respir Res. 2020 Nov 2;21(1):290.|Respir Res. 2020 Feb 19;21(1):58. |Toxicol Lett. 2022 Apr 23;363:45-54.|Universidad de las Illes Balears. Facultad de Ciencias, 2022 Feb.|Biomed Pharmacother. 2024 Jan 15:171:116101.|Biomedicines. 2023, 11(2), 463.|BMC Pharmacol Toxicol. 2024 Feb 14;25(1):18.|BMC Pulm Med. 2023 Nov 13;23(1):440.|Cancer Lett. 2023 Feb 15;558:216092.|Exp Ther Med. 2024 Jan 4.|Front Biosci (Landmark Ed). 2023 Sep 22, 28(9), 209.|Inflammation. 2023 May 9.|Inflammation. 2024 Mar 18.|Int Immunopharmacol. 2022, 113: 109409.|Int Immunopharmacol. 2023 May 22;120:110369.|Int J Biol Macromol. 2023 Apr 17;124476.|J Gene Med. 2022 Sep 30;e3451.|MedComm. 2023 Jul 12;4(4):e319.|Mol Med. 2023 Mar 14;29(1):32.|Molecules. 2023, 28(2), 753.|Nat Commun. 2022 Nov 17;13(1):7028.|Phytomedicine. 2023 Jun 17, 154919.|Research Square Preprint. 2023 Aug 3.|Transl Res. 2023 Feb 6;S1931-5244(23)00018-X.
• Shipping Conditions: Room Temperature
• Clinical Information: Launched